Overall survival rates and avoidance of disease progression were strongly correlated with cytogenetic response by 12 months; those with a minimal or no cytogenetic response within the first year faired poorly.

• 总体生存率和病情恶化停止与患者服药12个月后细胞遗传学反应密切相关，那些在第一年里没有或只有很小细胞遗传学反应的患者预后较差。